title: Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.
abstract: The results of antiviral therapy for hepatitis C virus (HCV) have improved recently with the use of pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy. At this point, most patients with chronic HCV remain untreated. Thus, it is anticipated that therapy will be more appealing and prescribed more broadly than in the past, including in patients considered marginal.
  
  
  OBJECTIVE
  To examine the effects of PEG-IFN-based antiviral therapy in elderly patients with chronic HCV.
  
  
  METHODS
  The charts of patients treated with chronic HCV were reviewed. Patients were defined as elderly if they were 60 years of age or older. The control group consisted of patients younger than 60 years of age who were matched to the treated elderly patients based on sex, treating physician, prescribed treatment and intended prescribed treatment duration. The data recorded included end of treatment response, sustained virological response (SVR), adverse events, dose modification and withdrawal of therapy.
  
  
  RESULTS
  Thirty of 147 (20.4%) elderly patients attending a hepatitis C clinic were treated. The average age of the elderly patients was 65+/-4 years. Forty-three per cent were men and 57% were women. Ten per cent received IFN monotherapy, 70% received a combination of IFN/RBV therapy and 20% received a combination of PEG-IFN/RBV therapy. The overall response rates in the elderly patients compared with the younger patients was 46.7% versus 65.8% (P=0.11) for end of treatment response and 33.3% versus 51.2% (P=0.13) for SVR. The rate of dose modification was 50% in the elderly patients compared with 29% in the control group (P=0.08). Therapy was discontinued in 53% of the elderly compared with 34% of younger patients (P=0.17). The younger patients reported more side effects than elderly patients; although, there were more laboratory abnormalities (anemia, thrombocytopenia and neutropenia) in the elderly patients during therapy than in the younger group (0.93 per patient versus 0.49 per patient, P=0.01).
  
  
  CONCLUSIONS
  Elderly patients with chronic HCV can be treated successfully. However, they are more at risk to develop cytopenias while on treatment. In such patients, the close monitoring of blood counts is necessary. Larger studies are needed to confirm these findings and to determine whether SVR differs in this population.
authors.affiliation: Department of Medicine, McGill University Health Centre, Montreal, Canada.
authors.forename: C G
authors.initials: CG
authors.lastname: Nudo
authors.forename: P
authors.initials: P
authors.lastname: Wong
authors.forename: N
authors.initials: N
authors.lastname: Hilzenrat
authors.forename: M
authors.initials: M
authors.lastname: Deschênes
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000453:epidemiology; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D011792:Quebec / Q000453:epidemiology; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007372:Interferons; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a